Value-Based Care

Fears that the telemedicine boom would send health care costs soaring haven’t been borne out, a major new study finds, and the timing couldn’t be more critical for federal policy makers.

Muhammad Bilal Abid, MD, discusses COVID prevention gaps, monoclonal antibodies, and infection risk in immunocompromised patients with CLL.

Chris Johnson, MBA, explains how retail-based pediatric clinics and smart tech can expand Medicaid access and streamline visits.

Progressive care management approaches can enable meaningful, patient-centric outcomes without assuming risk.

Experts discussed value-based oncology care, CAR T-cell therapy access gaps, myeloma advances, and bispecific therapy challenges.

Experts examined oncology care innovation, access gaps to CAR T-cell therapy, advances in myeloma care, and partnerships in value-based care.

OCM showed no increased likelihood of starting systemic therapy in patients with newly diagnosed cancers, despite gains in poor-prognosis cases.

RSV vaccines and nirsevimab are linked to reduced infant hospitalizations, though seasonal spikes and data limitations remain concerns.

Speakers at the NAACOS Spring 2026 Conference illustrated means of using technology in value-based care to implement preventive medicine.

OUD diagnoses have declined, but use of medication to treat OUD has increased among Medicaid beneficiaries, highlighting policy gains and ongoing state-level disparities.

Experts at AMCP 2026 urged smarter oncology management amid rising costs, complex therapies, and fragmented oversight across plans.

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies.

Value-based care in oncology: why CMS’ models have fallen short and how new partners can sustain navigation, symptom monitoring, and savings.

Experts outline 4 roles within the value-based care ecosystem that will make it more cohesive and effective for patients.

Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and formulary incentives.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

LLMs may improve pediatric clinical decision-making, but gaps in safety, accuracy, and pediatric-specific data remain.

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred during this February IVBM in Los Angeles.

March marks the 10th anniversary of the CDC's opioid prescribing guidelines for patients with chronic pain, which were later updated to expand their scope.

Discussions about drug pricing require consideration of values and preferences, according to Jonathan D. Campbell, PhD, chief science officer of the National Pharmaceutical Council.

Panelists at a Boston Regional Institute for Value-Based Medicine event examined trial diversity, integrated dispensing, and evolving oncology pathways.

Thyme Care bets on ePRO-driven toxicity monitoring to cut Medicare oncology adverse events, infections and ED visits—making value-based care finally work.

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.

Experts discussed how systemic changes need to be made to help improve preventive care access, which in turn can improve outcomes.

Accountable care experts say the future of value in Medicare will rely on scaling up innovation, emphasizing downstream prevention, and staying alert to waste.